The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12625001023448
Ethics application status
Approved
Date submitted
26/08/2025
Date registered
16/09/2025
Date last updated
16/09/2025
Date data sharing statement initially provided
16/09/2025
Type of registration
Prospectively registered

Titles & IDs
Public title
Piloting Implementation Strategies for Clinicians: Cardiovascular Rehabilitation for transient ischemic Attack and Mild Stroke
Scientific title
From research to practice: piloting and evaluating clinical implementation strategies for Cardiovascular Rehabilitation for transient ischemic Attack and Mild Stroke
Secondary ID [1] 315232 0
None
Universal Trial Number (UTN)
Trial acronym
CRAMS 2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
transient ischaemic attack 338687 0
stroke 338688 0
Condition category
Condition code
Cardiovascular 334970 334970 0 0
Other cardiovascular diseases
Stroke 334971 334971 0 0
Ischaemic
Physical Medicine / Rehabilitation 334972 334972 0 0
Other physical medicine / rehabilitation

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This study will evaluate the potential effectiveness of implementation strategies targeted at improving uptake (clinician referral and delivery) of cardiac rehabilitation programs that include people with TIA or mild stroke, alongside people with Coronary Heart Disease (CHD), within one health service (Canberra Health Services) (North Canberra Hospital and The Canberra Hospital).

Phase II cardiac rehabilitation in Australia is multidisciplinary, time-limited (e.g. 6-weeks), conducted in groups, health service-based, and has educational and supervised exercise components. The aim of the individually tailored exercise sessions is to increase exercise capacity, and education sessions aim to increase the patient’s knowledge of their cardiovascular disease condition and increase risk factor self-management skills. In this study, people with TIA and mild stroke will be referred to, and included in the delivery of existing outpatient cardiac rehabilitation programs at two sites, The Canberra Hospital (TCH) and North Canberra Hospital (NCH). No modifications to existing cardiac rehabilitation exercise sessions are required for this study, however the inclusion of the above brain, ischemic stroke and TIA education as part of existing education sessions will be encouraged to promote integration

A multi-component implementation strategy intervention will be developed to increase the number of people with TIA or mild stroke who have been referred, commenced and completed cardiac rehabilitation. To achieve this, this study will be conducted in three phases over 12 months.

• Phase 1 (3-months): The ‘Experience based co-design toolkit for Australia’ five-step methodology will be used to develop and refine the implementation strategies: 5-10 stroke and cardiac rehabilitation clinicians, managers and TIA or mild stroke patients will be recruited to participate in 3-4 workshop to develop the implementation strategy intervention and provide feedback. Workshops will be facilitated by an experienced qualitative researcher and audio recorded and will occur approximately 2 weeks apart over a 2 month period. Workshop 1 will outline the project aims, providing background information before breaking into smaller groups for brainstorming and discussion to explore factors influencing the uptake (referral and delivery) of cardiac rehabilitation for people with TIA or mild stroke. The group will return together to summarize ideas and themes. Workshop 2, and 3 if needed, will begin with a summary of key themes and ideas from the previous workshop. Participants will be asked to identify feasible strategies to address the factors identified in workshop 1 that could increase the uptake (referral and delivery) of cardiac rehabilitation among people with TIA and mild stroke in existing services. Researchers will facilitate discussions and encourage stakeholders to problem-solve to reach agreement, utilizing information gathered from previous research. The Consolidated Framework for Implementation Research (CFIR) and the Theoretical Domains Framework (TDF) will be used to underpin the development and refinement of the implementation intervention and identify factors influencing potential implementation during the co-design process. A final workshop will be held once implementation strategies and resources have been developed by researchers, to provide feedback and finalize the overall implementation intervention.

• Phase 2 (the 3-months following phase 1): The multi-component implementation intervention will be delivered by the research team to stroke and cardiac rehabilitation clinicians, supporting cardiac rehabilitation uptake by people with TIA or mild stroke in their routine practice. The delivery of the implementation intervention will be largely contingent on the outcomes of phase 1 and hence further specifics cannot be provided at this time, however based on prior research this may include establishment of clear referral pathways and eligibility criteria, delivery of education to stroke or cardiac rehabilitation clinicians or increasing program awareness.

• Phase 3 (the 12-months following phase 2): The stroke and cardiac rehabilitation clinicians will be encouraged to utilise the implementation intervention over 12-months to support referral to and delivery of cardiac rehabilitation for people with TIA or mild stroke. We will then evaluate the effectiveness of the implementation strategy intervention at mid and end time-points of implementation strategy intervention rollout, over the 12 month period.

With informed consent, participants in this study will participate in co-design workshops (phase 1, first 3 months), interviews with research staff (phase 3, final 12 months), and an online survey (phase 3, final 12 months). Semi-covert observations of clinical settings to observe the use of implementation strategies will also be conducted by research staff in phase 3 (12 months). A resources and training log will be kept to log details on clinician training provided during delivery of the implementation strategy intervention (phase 2), and associated costs of the delivery. For the pre-post implementation comparison component of the study, hospital administrative data will be collected at the start and end of the 12-month implementation strategy intervention roll-out period, and will include number people with TIA or mild stroke referred, commenced and completed the cardiac rehabilitation program. No identifiable patient data will be collected.
Intervention code [1] 331844 0
Treatment: Other
Comparator / control treatment
A control period will be used only for hospital administrative data. Hospital administrative data will include the number of people with TIA or mild stroke that were referred, commenced and completed cardiac rehabilitation, and will be collected for the 12 months prior to roll out of implementation strategies. There is no direct involvement with participants or patients here.
Control group
Historical

Outcomes
Primary outcome [1] 342603 0
The primary implementation outcome is reach of cardiac rehabilitation for people with TIA or Mild stroke. That is, the number and proportion of the intended priority population (people with TIA or mild stroke) referred, commenced or completed the cardiac rehabilitation program.
Timepoint [1] 342603 0
At the start of implementation strategy intervention evaluation period (phase 3). At the end of implementation strategy intervention evaluation period (12 months following roll-out of the implementation strategies) (phase 3).
Secondary outcome [1] 451503 0
Acceptability of implementation strategies: The perception among clinicians’ that the implementation strategies are agreeable or satisfactory.
Timepoint [1] 451503 0
Mid-way through the implementation strategy intervention evaluation period (6-months following roll-out of the implementation strategies, phase 3). At the end of implementation strategy intervention evaluation period (12 months following roll-out of the implementation strategies, phase 3) (survey only conducted at the end and not mid-way).
Secondary outcome [2] 451504 0
Adoption of implementation strategies: The clinicians’ decision to employ the implementation strategies and the factors influencing this will be assessed.
Timepoint [2] 451504 0
Mid-way through the implementation strategy intervention evaluation period (6-months following roll-out of the implementation strategies, phase 3). At the end of implementation strategy intervention evaluation period (12 months following roll-out of the implementation strategies, phase 3)
Secondary outcome [3] 451505 0
Appropriateness of implementation strategies: The clinicians’ perception of how well the implementation strategies fit within their setting, existing workflow, role or skill set. This includes their perception on whether the strategies are suitable for supporting the inclusion of people with TIA and mild stroke in existing cardiac rehabilitation services.
Timepoint [3] 451505 0
Mid-way through the implementation strategy intervention evaluation period (6-months following roll-out of the implementation strategies, phase 3). At the end of implementation strategy intervention evaluation period (12 months following roll-out of the implementation strategies, phase 3) (survey only conducted at the end and not mid-way).
Secondary outcome [4] 451507 0
Feasibility of the implementation strategies: The extent to which the implementation strategies can be successfully used in existing stroke and cardiac rehabilitation settings.
Timepoint [4] 451507 0
Mid-way through the implementation strategy intervention evaluation period (6-months following roll-out of the implementation strategies, phase 3). At the end of implementation strategy intervention evaluation period (12 months following roll-out of the implementation strategies, phase 3) (survey only conducted at the end and not mid-way).
Secondary outcome [5] 451516 0
Fidelity of the implementation strategies: The degree to which the implementation strategies were utilised as intended.
Timepoint [5] 451516 0
During delivery of the implementation strategy intervention to clinicians (over 3-months during phase 2) (only notes recorded in the resources and training log will be collected at this timepoint) Mid-way through the implementation strategy intervention evaluation period (6-months following roll-out of the implementation strategies, phase 3). At the end of implementation strategy intervention evaluation period (12 months following roll-out of the implementation strategies, phase 3)
Secondary outcome [6] 451517 0
Cost of the implementation strategies: The cost of the implementation strategies used to support referral to and delivery of the integrated cardiac rehabilitation program within existing health service structures.
Timepoint [6] 451517 0
During delivery of the implementation strategy intervention to clinicians (over 3-months during phase 2) (only notes recorded in the resources and training log will be collected at this timepoint) Throughout the implementation strategy intervention evaluation period (up to 12-months following roll-out of the implementation strategies, phase 3) so as to accurately record any further training costs incurred throughout this period.
Secondary outcome [7] 451518 0
Penetration of the implementation strategies: The integration of the implementation strategies within the stroke service and cardiac rehabilitation clinical settings.
Timepoint [7] 451518 0
Mid-way through the implementation strategy intervention evaluation period (6-months following roll-out of the implementation strategies, phase 3). At the end of implementation strategy intervention evaluation period (12 months following roll-out of the implementation strategies, phase 3)

Eligibility
Key inclusion criteria
Participants will be recruited during phase 1 and 3 of the study.

Eligibility - Phase 1:
- Eligible clinicians and managers must be employed within the stroke services or outpatient cardiac rehabilitation at either North Canberra Hospital (NCH) or The Canberra Hospital (TCH) during October 2025 – December 2025.
- Eligible consumers must have lived experience of TIA or mild stroke.

Eligibility - Phase 3:
- Eligible clinicians must be employed within the stroke services or outpatient cardiac rehabilitation at either site during the study period (March 2026 – April 2027), and be actively involved in referral or delivery of cardiac rehabilitation for people with TIA or mild stroke.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
None

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 0
Type of endpoint/s
Statistical methods / analysis
A mixed-methods evaluation of processes and outcomes will be conducted, involving quantitative and qualitative data analysis.

Quantitative hospital administrative data, implementation intervention cost, demographic characteristics and outcomes from the surveys will be analysed by the two lead investigators using descriptive statistics with appropriate statistical software. Continuous variables will be summarised using means and standard deviations (SD) or medians with interquartile ranges (IQR) or ranges, as appropriate. Categorical variables will be reported as frequencies and percentages. For cost, equipment and materials resources costs, total labour time, labour time per site, and associated monetary values will be calculated.

Qualitative data will be analysed deductively using framework analysis. Throughout phase 1 qualitative data, alongside findings from our previous ACT Health funded type I hybrid trial, will be mapped to the Theoretical Domains Framework (TDF) and the Expert Recommendations for Implementing Change (ERIC) matching tool. Throughout phase 3, qualitative data evaluating the use of the implementation intervention will be deductively mapped to the Consolidated Framework for Implementation Research (CFIR). A priori codebook will developed to guide deductive framework analysis. Data will be analysed by two researchers trained and experienced in qualitative research, following the five stages of framework analysis.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT
Recruitment postcode(s) [1] 44609 0
2617 - Bruce
Recruitment postcode(s) [2] 44610 0
2605 - Garran

Funding & Sponsors
Funding source category [1] 319797 0
Hospital
Name [1] 319797 0
Canberra Health Services
Country [1] 319797 0
Australia
Funding source category [2] 319798 0
University
Name [2] 319798 0
University of Canberra Health Research Institute
Country [2] 319798 0
Australia
Primary sponsor type
Individual
Name
Lucy Walton, University of Canberra and Canberra Health Services
Address
Country
Australia
Secondary sponsor category [1] 322313 0
Individual
Name [1] 322313 0
Nicole Freene, University of Canberra
Address [1] 322313 0
Country [1] 322313 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 318356 0
ACT Health Human Research Ethics Committee
Ethics committee address [1] 318356 0
Ethics committee country [1] 318356 0
Australia
Date submitted for ethics approval [1] 318356 0
25/08/2025
Approval date [1] 318356 0
03/09/2025
Ethics approval number [1] 318356 0
Regis reference: 2025/ETH01796, ACT Reference: 2025.LRE.00235

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 143922 0
Miss Lucy Walton
Address 143922 0
University of Canberra, University Drive, Bruce, ACT, 2617
Country 143922 0
Australia
Phone 143922 0
+61 488964402
Fax 143922 0
Email 143922 0
Contact person for public queries
Name 143923 0
Lucy Walton
Address 143923 0
University of Canberra, University Drive, Bruce, ACT, 2617
Country 143923 0
Australia
Phone 143923 0
+61 488964402
Fax 143923 0
Email 143923 0
Contact person for scientific queries
Name 143924 0
Lucy Walton
Address 143924 0
University of Canberra, University Drive, Bruce, ACT, 2617
Country 143924 0
Australia
Phone 143924 0
+61 488964402
Fax 143924 0
Email 143924 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.